αEβ7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis. by Lamb, Christopher A et al.
© European Crohn’s and Colitis Organisation 2016. 610
Journal of Crohn's and Colitis, 2017, 610–620
doi:10.1093/ecco-jcc/jjw189
Advance Access publication December 7, 2016
Original Article
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits 
unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Original Article
αEβ7 Integrin Identifies Subsets of  
Pro-Inflammatory Colonic CD4+ T Lymphocytes 
in Ulcerative Colitis
Christopher A. Lamb,a,b John C. Mansfield,b,c Gaik W. Tew,d  
Deena Gibbons,e,f Anna K. Long,g Peter Irving,e,h Lauri Diehl,d  
Jeff Eastham-Anderson,d Maria B. Price,b Graeme O’Boyle,a,†  
David E. J. Jones,a Sharon O’Byrne,d,‡ Adrian Hayday,e,f  
Mary E. Keir,d,* Jackson G. Egen,d,*,§ John A. Kirbya,*
aInstitute of Cellular Medicine, Newcastle University, Newcastle upon Tyne NE2 4HH, UK bDepartment of Gastroenterology, 
Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK cInstitute of Genetic Medicine, 
Newcastle University, Newcastle upon Tyne NE1 3BZ, UK dResearch & Early Development, Genentech, South San 
Francisco, CA 94080, USA ePeter Gorer Department of Immunobiology, King’s College London, London SE1 9RT, UK 
fLondon Research Institute, Cancer Research UK, London WC2, UK gDepartment of Cellular Pathology, Newcastle upon 
Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK hDepartment of Gastroenterology, Guys and St 
Thomas’ NHS Foundation Trust, London SE1 7EH, UK
*These authors contributed equally.
†Present address: Faculty of Applied Sciences, University of Sunderland, Sunderland SR1 3SD, UK
‡Present address: Global Medical Affairs Specialty GI, Takeda Pharmaceuticals International AG, Thurgauerstrasse 130, 
8152 Glattpark-Opfikon, Zurich, Switzerland
§Present address: Oncology Research, Amgen Inc, South San Francisco, CA 94080, USA
Corresponding author: John Kirby, DPhil, Institute of Cellular Medicine, Applied Immunobiology and Transplantation Re-
search Group, 3rd Floor William Leech Building, Newcastle University, Medical School, Framlington Place, Newcastle upon 
Tyne NE2 4HH, UK. Tel.: +44 191 222 7057; fax: +44 191 222 5851; e-mail: john.kirby@ncl.ac.uk
Conference presentation: Earlier versions of this work were presented at European Crohn’s and Colitis Organisation 
[ECCO], Digestive Diseases Week [DDW] and British Society of Gastroenterology [BSG] conferences in 2014: Lamb CA, 
Mansfield JC, Tew GW, et al. Ulcerative colitis: The αEβ7 integrin is associated with a high frequency of Th17, Th1 and 
Th17/Th1 CD4 lymphocytes. 
J Crohns Colitis 2014;8 Suppl 1:S18–19. 
Gastroenterology 2014;146 Suppl 1:S826. 
Gut 2014;63 Suppl 1:A71.
Abstract
Background and Aims: The αEβ7 integrin is crucial for retention of T lymphocytes at mucosal 
surfaces through its interaction with E-cadherin. Pathogenic or protective functions of these cells 
during human intestinal inflammation, such as ulcerative colitis [UC], have not previously been 
defined, with understanding largely derived from animal model data. Defining this phenotype in 
human samples is important for understanding UC pathogenesis and is of translational importance 
for therapeutic targeting of αEβ7–E-cadherin interactions.
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Methods: αEβ7+ and αEβ7− colonic T cell localization, inflammatory cytokine production and 
expression of regulatory T cell-associated markers were evaluated in cohorts of control subjects 
and patients with active UC by immunohistochemistry, flow cytometry and real-time PCR of FACS-
purified cell populations.
Results: CD4+αEβ7+ T lymphocytes from both healthy controls and UC patients had lower 
expression of regulatory T cell-associated genes, including FOXP3, IL-10, CTLA-4 and ICOS in 
comparison with CD4+αEβ7− T lymphocytes. In UC, CD4+αEβ7+ lymphocytes expressed higher 
levels of IFNγ and TNFα in comparison with CD4+αEβ7− lymphocytes. Additionally the CD4+αEβ7+ 
subset was enriched for Th17 cells and the recently described Th17/Th1 subset co-expressing 
both IL-17A and IFNγ, both of which were found at higher frequencies in UC compared to control.
Conclusion: αEβ7 integrin expression on human colonic CD4+ T cells was associated with increased 
production of pro-inflammatory Th1, Th17 and Th17/Th1 cytokines, with reduced expression 
of regulatory T cell-associated markers. These data suggest colonic CD4+αEβ7+ T cells are pro-
inflammatory and may play a role in UC pathobiology.
Key Words:  ulcerative colitis; inflammatory bowel disease; αEβ7 integrin; CD103; etrolizumab; intraepithelial lymphocytes; Th1; 
Th17; Th17/1; regulatory T cell; Treg; cytokine; CD4+ T cell; mucosal immunology; effector T cell; helper T cell
1. Introduction
Expression of the β7 integrin on lymphocytes mediates critical 
functions in mucosal immunity. This subunit is only present in two 
heterodimeric integrins, α4β7 and αEβ7.1 Therapeutic targeting 
of α4β7:MAdCAM-1-mediated lymphocyte trafficking to the gut 
in inflammatory bowel disease [IBD] has been clinically validated. 
Treatment with natalizumab, a humanized monoclonal antibody 
directed against the α4 integrin subunit, demonstrated clinical effi-
cacy in Crohn’s disease,2,3 but was also associated with progres-
sive multifocal leukoencephalopathy,4 presumably resulting from 
impaired α4β1 integrin-mediated lymphocyte homing to the central 
nervous system and/or mobilization of CD34+ JC virus-contain-
ing stem cells from bone marrow.5 More recently, vedolizumab, a 
humanized monoclonal antibody specific for the α4β7 integrin het-
erodimer, demonstrated efficacy in both Crohn’s disease and UC.6,7
In addition to the α4β7 integrin heterodimer, β7 integrin can 
also pair with αE [CD103]. The resulting αEβ7 integrin heterodimer 
is predominantly expressed on mucosal lymphocytes and dendritic 
cells,8 where it plays a role in cellular retention through adhesive 
interactions with E-cadherin expressed on the surface of epithelial 
cells.9 Transcription of the αE integrin subunit is induced by trans-
forming growth factor [TGF]β1,10 which is highly expressed in 
mucosal tissues by epithelial cells,11 suggesting that differentiation 
to and maintenance of an αEβ7+ phenotype occurs in proximity to 
the epithelial compartment. In support of this, >85% of intraepithe-
lial lymphocytes [IELs] and ~40% of lamina propria lymphocytes 
[LPLs] in the small intestine are αEβ7+.12 αE-deficient mice have 
reduced numbers of IELs and LPLs in the intestine, while Peyer’s 
patches [PPs] and splenic lymphocyte populations remain intact.13 
Additionally, β7-deficient mice lack both α4β7 and αEβ7 integrin 
expression and have severely impaired gut-tropic lymphocyte migra-
tion, leading to poorly developed PPs with diminished cellularity.14
Although αEβ7+ cells have been studied in mouse models,15–22 
there are only limited data on these cells in the human gut, and the 
role of these cells in human colitis is not understood. Several studies 
in mice have highlighted αE expression as a marker of distinct and 
highly suppressive regulatory T cell [TReg] populations, although 
suppressive activity is also observed in αE− populations.15–18 
Highlighting the potential for αE to mark effector populations in 
murine studies, αE blockade can be beneficial in mouse models of 
colitis,19 graft-versus-host disease-associated intestinal inflamma-
tion20 and solid organ transplant.21,22 The role that αEβ7+ T cells 
play in the normal and inflamed human intestine is still unclear.
Etrolizumab is a humanized monoclonal antibody specific for the 
β7 integrin subunit and therefore targets both intestinal lymphocyte 
recruitment and retention by binding, respectively, the α4β7 and αEβ7 
integrins. This is in contrast to the mechanism of action of natali-
zumab and vedolizumab that target lymphocyte recruitment alone by 
binding α4- and α4β7-mediated homing, respectively. The additional 
blockade of αEβ7 integrin represents a unique potential mechanism 
of action, and this therapeutic approach has shown efficacy in mod-
erate to severely active UC.23,24 The relative impact of etrolizumab-
mediated α4β7 vs αEβ7 integrin blockade on patient response is at 
present unclear. However, a retrospective analysis of Phase II data in 
UC observed increased clinical remission among patients with higher 
expression levels of αE at baseline in comparison to patients with 
lower levels of αE at baseline, suggesting that αE+ cells may be predic-
tive for response to drug therapy.24,25 Understanding the role of αEβ7+ 
T cells in humans is essential to safely and most effectively use etroli-
zumab therapy in the correct patients and to the best advantage.
To better understand the role of these cells in intestinal inflamma-
tion, we evaluated expression of inflammatory and regulatory mark-
ers in αEβ7+ and αEβ7− colonic T lymphocytes in patients with 
active UC in comparison to healthy control subjects. This analysis 
of αEβ7+ and αEβ7− colonic T lymphocytes will help to understand 
the role of the αE integrin in disease pathogenesis, as well as offer-
ing insight into the mechanism of etrolizumab and the potential role 
of this integrin as a biomarker for therapeutic stratification in IBD.
2. Methods
2.1. Participants and disease stratification
Patients with active UC on stable therapy and healthy control subjects 
[Table 1] were enrolled in prospective tissue repositories at Newcastle 
University and King’s College London [KCL], UK. Specimens from 
the Newcastle cohort were investigated for protein expression by 
immunohistochemistry and flow cytometry, and specimens from the 
KCL cohort were investigated for gene expression by quantitative 
polymerase chain reaction [qPCR]. The aim of this approach was 
to confirm cellular phenotypic associations by multiple scientific 
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modalities and in distinct geographical patient populations. Enrolled 
healthy control subjects had normal colonic mucosa undergoing 
routine endoscopy [e.g. for investigation of iron deficiency anaemia 
or for polyp surveillance]. All patients were naïve to therapies tar-
geting integrins [etrolizumab, vedolizumab and natalizumab], and 
tumour necrosis factor [TNF]α [infliximab and adalimumab]. UC 
patients were considered to have active disease if they had a Mayo 
endoscopic subscore26 of 1 or more; UC patients with endoscopic 
subscores of 0 were not included in this study. In total, 35 control 
subjects and 27 UC patients provided tissue for research. These stud-
ies were performed according to the principles of the Declaration of 
Helsinki. Written informed consent was obtained in accordance with 
research and ethics committee [REC] approval [Newcastle and North 
Tyneside 1 REC 10/H0906/41, Newcastle and North Tyneside 2 REC 
22/02 and Wandsworth REC 07/H0803/237].
2.2. Tissue handling
Colonic mucosal biopsies were obtained at the time of colonoscopy 
or flexible sigmoidoscopy, and collected from the distal colon to 
avoid anatomical variations in lymphocyte phenotype or frequency. 
Between four and eight biopsies were collected per patient with a 
yield of approximately 75 000–100 000 T cells from each biopsy. 
Specimens for immunohistochemistry [IHC] analysis were fixed 
immediately in neutral buffered formalin prior to paraffin embed-
ding. Fresh tissue was stored in Hank’s balanced salt solution [HBSS] 
with or without calcium or magnesium [Gibco, Carlsbad, CA, USA] 
on ice for up to 2 h until enzymatic dissociation.
2.3. Colonic biopsy dissociation and lymphocyte 
enrichment
Biopsies were washed in HBSS containing 5 mM 1,4-dithiothrei-
tol [DTT, Sigma-Aldrich, St Louis, MO, USA] prior to enzymatic 
tissue dissociation using 10% complete RPMI containing 1.5 mg/
ml Collagenase VIII [Sigma-Aldrich] and 50 microg/ml DNase I 
[Roche, Penzberg, Germany]. The resultant cell suspension was 
filtered through a 40-μm cell strainer and washed with FACS buffer 
to collect any residual cells prior to centrifugation and staining.
2.4. Cell surface and intracellular protein 
quantification by flow cytometry
Viable cells were identified using a Live/Dead fixable aqua dead cell 
stain kit [Invitrogen, Grand Island, NY, USA] according to the man-
ufacturer’s instructions. For identification of cell surface proteins, 
cells were suspended in 2% fetal calf serum PBS and incubated for 
10 min with human FcR blocking reagent [Miltenyi Biotec, Bergisch 
Gladbach, Germany], prior to the addition of optimized concentra-
tions of fluorochrome-tagged anti-αE, -β7, -α4β7, -CD45, -CD3, 
-CD4, -CD8a, -CD161 or isotype control antibodies and incubated 
for 20  min [Supplementary Table  1]. Gating strategies to identify 
lymphocyte populations are shown in Supplementary Fig 1.
For identification of intracellular proteins, ex-vivo cells were left 
unstimulated or stimulated at 37 °C in 5% CO2 for 5 h in the presence 
of 10 ng/ml phorbol 12-myristate 13-acetate [PMA] and 1 μg/ml iono-
mycin, with the addition of 10 ng/ml brefeldin A [all Sigma Aldrich] after 
1 h. Cells were fixed for 30 min in 4% paraformaldehyde fixation buffer 
[Biolegend, San Diego, CA, USA], prior to washing with and suspending 
in permeabilization buffer [eBioscience, San Diego, CA, USA], and then 
stained for 30 min with optimized concentrations of anti-IL-17A, -IFNγ, 
-TNFα or isotype control antibodies [Supplementary Table 1].
Data were acquired using a BD FACSCanto II flow cytometer 
using FACSDiva software v6 [Becton Dickinson, Franklin Lakes, 
NJ, USA]. Analysis was performed using FlowJo software v9.4.7 
[TreeStar, Ashland, OR, USA]. Cell population gates were estab-
lished based on levels of background fluorescence in isotype control 
stained, or unstimulated samples.
2.5. qPCR analysis of colonic T cell subsets
T lymphocytes isolated from colonic biopsies and identified by 
flow cytometry as previously described25 were sorted using a 
Becton Dickinson FACS Aria II [SORP] cell sorter into four groups 
[CD4+αEβ7+, CD4+αEβ7−, CD8+αEβ7+ and CD8+αEβ7−] directly 
into RLT lysis buffer [Qiagen, Hilden, Germany] and stored at 
−80  °C prior to RNA extraction. cDNA synthesis was performed 
using the High-Capacity cDNA Reverse Transcription Kit [Life 
Technologies, Carlsbad, CA, USA], and quantitative real time PCR 
analysis was performed using the BioMark HD System [Fluidigm, 
South San Francisco, CA, USA] using Taqman gene expression of 
specified genes [Life Technologies]. All gene expression values were 
normalized to GAPDH expression using the ΔCT method.
2.6. Immunohistochemistry staining and 
quantification
IHC was performed on formalin-fixed and paraffin-embedded colonic 
biopsies. Blocks were cut into 4-μm sections and stained using a 
BenchMark Ultra autostainer [Ventana Medical Systems, Tucson, AZ, 
USA] with optimized concentrations of anti-αE integrin, FOXP3, CD3, 
CD4 and CD8 antibodies [Supplementary Table 2]. Slides were devel-
oped with Alkaline Phosphatase Red [Ventana Medical Systems] and 
Vina Green [Biocare Medical, Concord, CA, USA] chromogen kits.
Whole slide images were acquired with a Nanozoomer 2.0-HT 
automated slide-scanning platform [Hamamatsu, Hamamatsu City, 
Japan] at 200× final magnification. Scanned images were analysed in the 
Matlab software package vR2012b [Mathworks, Natick, MA, USA].
Images from IHC slides were captured on an Olympus BX61 
microscope [Olympus, Center Valley, PA, USA] outfitted with a 
Nuance Multispectral Imaging System [Perkin Elmer, Waltham, MA, 
Table 1. Summary of patient demographics.
Control UC
Patients [n] 35 27
Mayo endoscopy subscore [n]:
0 0
1 6
2 16
3 5
Gender: male/female [n] 19/16 17/10
Mean age at biopsy, years [range] 55 
[21–77]
45 [19–73]
Mean duration of disease, years [range] 9.8 [0.2–33]
Concomitant IBD medications [n]
Anti-TNF [infliximab, adalimumab] 0
Anti-leukocyte trafficking [etrolizumab,  
vedolizumab, natalizumab]
0
Immunomodulators [azathioprine,  
mercaptopurine, methotrexate, MMF]
8 [5, 0, 2, 1]
Systemic corticosteroid  
[oral prednisolone, intravenous hydrocortisone]
6 [5, 1]
Topical corticosteroid 4
5ASA 20
Topical 5ASA 2
No IBD meds 3
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USA]. A spectral library was created based on single colour pixel selec-
tion from each individual chromogen, allowing unmixing of multiple 
spatially co-localized chromogens. For each slide, a series of images 
was collected at a final magnification of 200x with exposure of 160 
ms and red, green and haematoxylin were unmixed. Using the spec-
trally unmixed images as a guide, areas were manually selected on the 
whole-slide scans specific to either single chromogen or co-localized 
chromogen. These areas were used to train a Support Vector Machine 
[SVM] on the RGB colour profile specific to those areas. Application 
of this SVM to the entire slide image resulted in three binary masks, 
one for each single or co-localized chromogen. Individual cell borders 
were segmented as described,27 and then scored IHC positive accord-
ing to the greatest contingent of staining present within its borders, 
with co-localized area given twice the weight of either single chromo-
gen, as well as at least ~10 µm2 of staining present.
Crypt epithelial areas were identified using a combination of an 
SVM and Genetic Programming [GP]. First, a training set of repre-
sentative areas was generated manually and assigned a binary classi-
fication [positive for crypt lumen, or negative for regions to exclude]. 
Then, an SVM was trained using RGB28 and texture values from 
these selections. GP was used to determine a sequence of simple mor-
phological operators that maximized the solution accuracy for both 
positive and negative selections. The resulting SVM and GP algo-
rithm was then applied to the entire set of images. Post-processing, 
any individual samples with less than 15 000 µm2 of total crypt area, 
or approximately three small crypts, were removed from the analy-
sis. The layer of cell nuclei immediately adjacent to the crypt lumen 
was identified by dilating the lumen areas approximately one cell 
diameter, and reconstructing the overlapping cells.
2.7. Statistics
Statistical analysis was performed using Prism5 [GraphPad soft-
ware, San Diego, CA, USA] and JMP11 [SAS, Cary, NC, USA]. The 
distributions of the samples were assessed for normality using the 
D’Agostino–Pearson omnibus test. Tukey box plots depict IHC 
and flow cytometry data. Intra-individual and inter-individual flow 
cytometry data were compared using paired and unpaired Student’s 
t-tests, respectively. Interleaved scatter plots depict qPCR data, and 
dotted lines on graphs represent the lower limit of detection for 
genes of interest. The Mann–Whitney U test was used to compare 
gene expression data for αE+ vs αE− cell populations. No adjust-
ment for multiple comparisons was performed, except where noted 
in the text. Statistical significance [p < 0.05] was defined based on 
nominal p-values, and different levels were noted on graphs as fol-
lows: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
3. Results
3.1. UC is associated with an expansion of  
αE− FOXP3+ cells in the lamina propria
Human studies have previously demonstrated an influx of TReg to 
the intestinal mucosa in active IBD by a combination of flow cytom-
etry, IHC and qPCR.29 We first sought to determine if T cells were 
the predominant leukocyte subset expressing αE during active UC, 
and whether there was any association of αE integrin with markers 
of regulatory T cell function.
Flow cytometry demonstrated a significant increase in total 
CD45+ leukocytes and CD3+ T cells in active UC in comparison to 
healthy subjects [Figure  1A&B] without a difference in CD4:CD8 
ratio [Figure 1C]. Of all αE+ leukocytes, CD3+ T cells represented 
the dominant leukocyte subset [Figure 1D]. In control subjects nearly 
90% of αE+ leukocytes were T cells, significantly rising to nearly 95% 
in UC. The frequency of α4β7 integrin expression was higher on αE+ 
relative to αE− T cells in both UC patients and controls [Figure 1E]. 
In addition, not all αE+ T cells expressed α4β7 as up to 40% of αE+ 
T cells in patients with active UC did not express α4β7 [Figure 1E].
We next examined the expression of αE integrin and the regula-
tory transcription factor FOXP3 using dual colour IHC. Consistent 
with preferential localization of αE+ cells to anatomical sites rich in 
E-cadherin, αE was predominantly observed on epithelial-associated 
CD3+, CD4+ and CD8+ cells with a high proportion of cells showing 
co-staining for T cell markers and αE [Supplementary Figure 2A–C]. 
Very few αE+FOXP3+ cells were observed in either the epithe-
lium or the LP, with a small but significant increase in epithelial-
associated cells [Figure 2A&B]. In contrast to the relative scarcity 
of αE+FOXP3+ cells, there was a marked expansion of FOXP3+ 
cells lacking the αE integrin in the LP of patients with active UC 
[Figure 2C]. The majority of αE+ cells were observed to be FOXP3−, 
with preferential localization to the epithelium [Figure 2D].
3.2. Human colonic CD4+αE− T cells display 
enhanced levels of TReg-associated genes 
compared with CD4+αE+ cells
An expansion of FOXP3+ cells in the LP during inflammation may be 
indicative of infiltrating/expanding TReg populations. However, acti-
vated effector T cells can express FOXP330 and so the transcription 
factor is not specific enough by itself to identify TReg. Human TReg 
have been shown to have high expression of IL-10, CTLA4, ICOS 
and GARP in addition to FOXP3.31–33 Therefore, gene expression of 
these TReg-associated markers was evaluated in purified αE+ and αE− 
subsets of both CD4+ and CD8+ TCRαβ+ T cells. Consistent with 
the IHC analysis, CD4+αE− T lymphocytes consistently expressed 
higher levels of TReg-associated genes in comparison to CD4+αE+ 
cells. Both in control subjects and more strikingly in UC patients, 
sorted CD4+αE− T cells had significantly higher levels of FOXP3, 
IL-10, CTLA4 and ICOS in comparison with CD4+αE+ T cells [Fig 
2E&F]. When correction was made for multiple comparisons using 
the Benjamini–Hochberg false detection rate adjustment of 10%, 
FOXP3 remained significantly elevated in CD4αE– vs CD4+αE+ T 
cells in both UC and control subjects. No difference in expression of 
TReg-associated genes was noted between CD8+αE+ and CD8+αE– 
lymphocytes in either group [Supplementary Figure 3A].
3.3. Expression of the αE integrin by colonic CD4+ T 
cells is associated with Th17 differentiation
These findings suggest that, in contrast to the mouse, αE is not a 
marker of TReg in the human colon. We next investigated if αE was 
associated with a pro-inflammatory T cell phenotype.
The RORC gene encodes a member of the nuclear hormone recep-
tor family of transcription factors, and is an important component of 
Th17 differentiation which has been associated with IBD in a num-
ber of studies.34,35 Relative gene expression levels of FOXP3, RORC 
and IL17A in CD4+αE+ and CD4+αE– T cells were therefore exam-
ined in our active UC cohort. In contrast to CD4+αE+ lymphocytes, 
CD4+αE– T lymphocytes had lower levels of RORC and IL17A, along 
with higher levels of FOXP3 expression [Fig 3A&B], suggesting that 
these CD4 subsets consist of T cells in unique states of differentiation.
To confirm the association of Th17 phenotype with αE integ-
rin expression, cellular cytokine production was examined by flow 
cytometry. Analysis of CD4+αE+ colonic lymphocytes revealed a 2- 
to 3-fold increased frequency of IL-17A+ cells in comparison with 
CD4+αE− lymphocytes [Figure 3C]. Furthermore, the frequency of 
IL-17A was twice as high in active UC CD4+αE+ cells compared to 
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control subject CD4+αE+ lymphocytes. Consistent with previous 
research showing that IL-17-producing T cells are enriched in the 
CD161+ population, the majority of CD4 cells expressing either 
IL-17A or αE also expressed surface CD161 [Figure 3D&E].36
In the CD8 compartment, αE+ cells from patients with active UC 
demonstrated a higher gene expression of IL-17A compared with 
CD8+αE− T cells, while no difference in gene expression was noted 
in control subjects [Supplementary Figure 3B]. However, FACS anal-
ysis of colonic ex vivo stimulated CD8+ T cells demonstrated very 
low frequency of IL-17A cytokine-producing cells irrespective of dis-
ease status or αE expression [Supplementary Figure 4A].
3.4. Higher production of Th1 cytokines is observed 
in CD4+αE+ relative to CD4+αE− colonic T cells
Given the association between Th17 differentiation and αE integrin, 
we next sought to determine whether CD4+αE+ T cells also had a 
Th1 phenotype using qPCR examination of T cells and flow cytom-
etry of PMA/ionomycin-stimulated colonic T cells. Sort-purified 
CD4+αE+ T cells from control subjects demonstrated higher gene 
expression of TNFα compared with CD4+αE− T cells. A  trend to 
higher IFNγ expression by CD4+αE+ T cells in control subjects was 
also observed [p = 0.09, Figure 4A].
The relationship of higher effector gene expression of sort-
purified CD4+αE+ T cells in comparison to CD4+αE− T cells was 
more striking in active UC patients [Figure 4B]. The frequency of 
IFNγ protein-expressing cells and the level of IFNγ transcripts were 
significantly increased in CD4+αE+ compared to CD4+αE− cells in 
UC patients, and the frequency of IFNγ-producing cells was overall 
decreased in the CD4+αE− population in patients with UC [Figure 
4C]. CD8+αE+ T cells also had increased IFNγ-expressing poten-
tial compared to CD8+αE– cells by protein and gene expression 
[Supplementary Figures 3B & 4B].
Similar relationships of protein and transcript level increases 
were observed for TNFα expression in the CD4+αE+ compared to 
CD4+αE- population [Figure 4A, B&D]. In contrast to these findings 
in CD4+ T cells, no difference in TNFα protein or gene expression 
was seen between CD8+αE+ and CD8+αE− cells [Supplementary 
Figures 3B & 4C].
Although gene expression of the Th2 cytokines IL-4 and IL-13 by 
CD4+ T cells in the colon was very low in both controls and UC, a 
small but significant increase in IL-4 gene expression in CD4+αE− cells 
relative to CD4+αE+ cells was observed [Figure 4A&B] in control sub-
jects and UC patients. An increase in IL-13 gene expression was also 
seen in CD4+αE- cells relative to CD4+αE+ cells in active UC.
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Figure 1. Ulcerative colitis is associated with an influx of mucosal leukocytes. Cells isolated from colonic biopsies sampled from control subjects [n = 14] and UC 
patients [n = 10] were evaluated by flow cytometry. Frequency of [A] CD45+ leukocytes, and [B] CD3+ T lymphocytes in the colonic mucosa is shown, along with [C] 
CD4:CD8 ratio of all CD3+ T cells and [D] representative αE vs CD3 FACS plots of CD45+ leukocytes, with summary graph of the proportion of CD45+αE+ leukocytes 
that were T cells. [E] In a subset of patients, surface expression of α4β7 dimer on αE+ and αE− T cells from control subjects [n = 6] and UC patients [n = 8] was examined.
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3.5. CD4+αE+ T cells display a Th17/Th1 phenotype 
that is exaggerated in UC
Recent studies have identified that in contrast to Th1 cells, which 
demonstrate stable lineage commitment after differentiation from 
naïve cells, Th17 cells retain some degree of plasticity which can 
give rise to so-called Th17/Th1 dual IL-17A-positive and IFNγ-
positive cells.37 These potentially pathogenic cells have previously 
been identified in Crohn’s disease.38 We therefore used flow cytom-
etry to explore if Th17/Th1 cells were present in UC and if there 
was any differential phenotype relative to αE expression. Dual 
IL-17A+IFNγ+ T cells were identified in control subjects and active 
UC [Figure 5A&B]. Notably, the frequency of dual cytokine-produc-
ing CD4+αE+ cells was increased 2-fold in UC compared to control 
tissue samples. CD8 lymphocytes had a very low potential to concur-
rently produce both IL-17A and IFNγ [Supplementary Figure 4D].
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subjects [n = 16] and patients with active UC [n = 14]. In a separate study cohort, FACS-sorted unstimulated CD4+αE+ and CD4+αE− colonic lymphocytes were 
analysed for TReg gene expression in [E] control subjects [n = 8] and [F] patients with active UC [n = 10].
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4. Discussion
A substantial fraction of gut-associated T lymphocytes express the αE 
integrin, yet the phenotype of these cells in humans and their potential 
contribution to diseases such as UC remain largely unknown. TGFβ, 
which plays a key role in the differentiation of both Th17 cells and 
induced TRegs depending on the cytokine milieu,37,39 also induces 
αE expression on T cells. In this study, utilizing two independent 
cohorts, one examined for protein expression by IHC and FACS and 
one examined for gene expression by qPCR, we consistently observed 
CD4+αE+ lymphocytes to be enriched in mucosal effector T cell popu-
lations expressing several inflammatory cytokines, including Th17 
and Th1, but not Th2. The recently described Th17/Th1 lineage cells, 
which express T-bet and RORC and are potentially potent effector 
T cells, were also increased within CD4+αE+ cells.37 Consistent with 
their increased expression of IL-17A, we found that the majority of 
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CD4+αE+ T cells also express CD161, a surface marker previously 
found to be highly enriched in the Th17 subset.36 These data suggest 
that TGFβ-driven differentiation into the Th17 lineage, rather than the 
Treg lineage, is favoured in CD4+αE+ T cells in the gut. Previous stud-
ies have identified Th17/Th1 lineage cells that are enriched in Crohn’s 
disease patients.37 Our data extend these findings into UC, indicating 
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that Th17/Th1 cells are present in UC and are most frequent in the 
CD4+αE+ population. In addition, CD4+αE+ cells in UC had higher 
transcription and expression of the pro-inflammatory cytokine TNFα, 
which although classically associated with Th1 cells, can also be pro-
duced by Th17 cells,40 suggesting that the pro-inflammatory functions 
of these cells may extend beyond production of only IL-17A and IFNγ.
As we observe substantial enrichment of regulatory markers in 
αE− human intestinal T cells, αE integrin is probably not an exclusive 
marker for regulatory T cells in humans. TRegs can suppress effec-
tor functions of other T lymphocytes, in part through the production 
of IL-10 and TGFβ1. In mice, TReg populations expressing αE have 
been identified and shown to suppress inflammation in a number of 
disease models, including colitis,17 chronic graft versus host disease18 
and antigen-induced arthritis.15 In human UC and control subjects we 
found CD4+αE+ lymphocytes have reduced transcription of the regu-
latory T cell-associated gene FOXP3 relative to their CD4+αE− coun-
terparts. Competitive antagonism has previously been demonstrated 
in transcription of FOXP3 and RORC, stabilizing, respectively, the 
TReg and Th17 phenotype.41 Consistent with these findings, we dem-
onstrated that CD4+ T cells sorted on the basis of αE surface expres-
sion and analysed for RORC and FOXP3 gene expression, cluster 
into RORChi FOXP3lo [CD4+αE+] and RORClo FOXP3hi [CD4+αE−] 
subsets, suggestive of distinct functions. Although FOXP3 may be 
expressed by activated30 or a minor non-regulatory T cell subset,42 
other regulatory T cell-associated genes [CTLA-4, GARP, ICOS, 
IL-10] were also upregulated in CD4+αE− T cells. While none of 
these genes are specific to TRegs, for instance IL-10 can also be 
produced by activated Th1 cells,43 the aggregate pattern of gene 
expression observed in this study suggests strongly that the major-
ity of human CD4+αE+ T cells do not have an enhanced regulatory 
function, and that the majority of T cell-mediated immunoregulatory 
activity is contained within the CD4+αE− population.
Taken together, these data support a model in which the mucosal 
CD4+αE+ population, already skewed towards an effector T cell pheno-
type in the steady state, becomes highly enriched in cells capable of pro-
ducing pro-inflammatory cytokines. These cytokines have been shown 
to contribute to the epithelial damage and dysfunction characteristic of 
UC.44–46 The mechanisms responsible for promoting the differentiation 
and activation of CD4+αE+ T cells in vivo remain largely unknown, but 
could involve factors directly produced by intestinal epithelial cells such 
as TGFβ1, which can induce αE expression and a Th17 phenotype.10,47 
Thus, cross-talk between CD4+ mucosal lymphocytes and dysfunc-
tional epithelial cells may contribute to the pathobiology of UC.9
Etrolizumab has recently demonstrated efficacy during a Phase II 
clinical trial in moderate to severe UC.24 This monoclonal antibody 
is selective for the β7 integrin subunit and thus targets both αEβ7 
and α4β7 integrin-expressing cells. Notably, etrolizumab treatment 
was associated with a significant reduction in the number of αE+ cells 
within the colonic epithelial compartment of patients responding to 
therapy. In addition, post-hoc analysis demonstrated higher remission 
rates in patients with higher baseline colonic αE expression as meas-
ured by IHC or whole-biopsy qPCR.24,25 Together with data presented 
in the current study, these findings suggest that blockade of αEβ7:E-
cadherin interactions by etrolizumab may interfere with epithelial cell–
lymphocyte localization48, and could function in combination with 
inhibition of α4β7:MAdCAM-mediated lymphocyte trafficking, or 
independently of α4β7 where αEβ7 is expressed in isolation, to reduce 
colonic inflammation in UC.24 It is not clear whether αE:E-cadherin 
interactions are required for effector T cell function, or whether αE 
is simply a biomarker of a cytokine-responsive mucosa-associated 
cell. Specifically, our study identified very limited phenotypic differ-
ences between αE+ and αE− colonic CD8+ T cells. However, αE is 
likely to influence the spatial localization of CD8+ T cells relative to 
the epithelium and the immunological synapse may influence release 
of cytotoxic granules. Thus, further study will be required in larger 
patient groups as well as additional studies focused on identifying the 
pathways responsible for CD4+αE+ and CD8+αE+ T cell recruitment, 
differentiation and activation in the absence and presence of factors 
blocking interaction of the integrin with E-cadherin.
The goal of personalized medicine in heterogeneous diseases 
such as UC, in which treatment paradigms are based on knowl-
edge of the underlying biology of disease using testable biomark-
ers or genetics, will require careful and iterative investigation of 
pathobiology in the context of clinical trials. Our findings highlight 
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the importance of establishing the function of cell populations in 
directly relevant human tissues and patient groups. Mixed results 
have been reported for the efficacy of targeting β7 integrins or cor-
responding cell adhesion molecules in murine models of IBD,49–54 
and one possible explanation is key species differences in function 
of leukocyte populations that are blocked from entry or retention 
within the gut. Differences in human cell biology demonstrated in 
this study from previous reported murine research highlight the 
importance of directly evaluating target cell populations in patient 
samples to ultimately enable appropriate patient selection strategies. 
The specific contribution of αE+ T cells to maintenance and loss of 
intestinal homeostasis will need to be evaluated in the context of 
integrin blockade in patients, ideally in ongoing Phase III studies, 
to further clarify the mechanisms by which integrin-targeted thera-
pies function in UC, and whether these cells may be of interest for 
patient-selection strategies.
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